nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—UGT1A9—Mycophenolic acid—psoriasis	0.0946	0.15	CbGbCtD
Regorafenib—UGT1A1—Mycophenolic acid—psoriasis	0.0774	0.122	CbGbCtD
Regorafenib—UGT1A9—Mycophenolate mofetil—psoriasis	0.0529	0.0836	CbGbCtD
Regorafenib—UGT1A1—Mycophenolate mofetil—psoriasis	0.0432	0.0684	CbGbCtD
Regorafenib—CYP2C8—Tazarotene—psoriasis	0.0342	0.0541	CbGbCtD
Regorafenib—ABCG2—Mycophenolate mofetil—psoriasis	0.0238	0.0376	CbGbCtD
Regorafenib—CYP2B6—Cholecalciferol—psoriasis	0.0193	0.0305	CbGbCtD
Regorafenib—ABCG2—Hydrocortisone—psoriasis	0.0191	0.0302	CbGbCtD
Regorafenib—ABCG2—Cyclosporine—psoriasis	0.018	0.0285	CbGbCtD
Regorafenib—CYP2C8—Cholecalciferol—psoriasis	0.0146	0.0231	CbGbCtD
Regorafenib—CYP2C8—Mycophenolate mofetil—psoriasis	0.0127	0.02	CbGbCtD
Regorafenib—CYP2C19—Cholecalciferol—psoriasis	0.0123	0.0194	CbGbCtD
Regorafenib—ABCG2—Dexamethasone—psoriasis	0.0119	0.0188	CbGbCtD
Regorafenib—CYP3A4—Calcitriol—psoriasis	0.0115	0.0182	CbGbCtD
Regorafenib—CYP2C9—Cholecalciferol—psoriasis	0.0102	0.0161	CbGbCtD
Regorafenib—CYP2C8—Hydrocortisone—psoriasis	0.0102	0.0161	CbGbCtD
Regorafenib—CYP2C8—Cyclosporine—psoriasis	0.0096	0.0152	CbGbCtD
Regorafenib—ABCG2—Methotrexate—psoriasis	0.00954	0.0151	CbGbCtD
Regorafenib—CYP3A4—Methoxsalen—psoriasis	0.00895	0.0141	CbGbCtD
Regorafenib—ABCB1—Mycophenolate mofetil—psoriasis	0.00858	0.0136	CbGbCtD
Regorafenib—CYP2C19—Prednisone—psoriasis	0.0085	0.0134	CbGbCtD
Regorafenib—CYP2B6—Dexamethasone—psoriasis	0.00835	0.0132	CbGbCtD
Regorafenib—DDR2—skin epidermis—psoriasis	0.00831	0.162	CbGeAlD
Regorafenib—CYP2C19—Cyclosporine—psoriasis	0.00805	0.0127	CbGbCtD
Regorafenib—ABCB1—Betamethasone—psoriasis	0.00736	0.0116	CbGbCtD
Regorafenib—ABCB1—Prednisolone—psoriasis	0.00726	0.0115	CbGbCtD
Regorafenib—ABCB1—Hydrocortisone—psoriasis	0.00688	0.0109	CbGbCtD
Regorafenib—ABCB1—Prednisone—psoriasis	0.00686	0.0108	CbGbCtD
Regorafenib—CYP2C9—Cyclosporine—psoriasis	0.0067	0.0106	CbGbCtD
Regorafenib—ABCB1—Cyclosporine—psoriasis	0.0065	0.0103	CbGbCtD
Regorafenib—CYP2C8—Dexamethasone—psoriasis	0.00632	0.01	CbGbCtD
Regorafenib—CYP3A4—Cholecalciferol—psoriasis	0.00593	0.00937	CbGbCtD
Regorafenib—CYP2C19—Dexamethasone—psoriasis	0.0053	0.00839	CbGbCtD
Regorafenib—CYP3A4—Mycophenolate mofetil—psoriasis	0.00514	0.00812	CbGbCtD
Regorafenib—CYP3A4—Triamcinolone—psoriasis	0.00514	0.00812	CbGbCtD
Regorafenib—CYP2C9—Dexamethasone—psoriasis	0.00441	0.00697	CbGbCtD
Regorafenib—CYP3A4—Betamethasone—psoriasis	0.00441	0.00697	CbGbCtD
Regorafenib—CYP3A4—Prednisolone—psoriasis	0.00435	0.00688	CbGbCtD
Regorafenib—ABCB1—Dexamethasone—psoriasis	0.00428	0.00677	CbGbCtD
Regorafenib—FGFR2—skin epidermis—psoriasis	0.00425	0.0827	CbGeAlD
Regorafenib—CYP3A4—Hydrocortisone—psoriasis	0.00412	0.00652	CbGbCtD
Regorafenib—CYP3A4—Prednisone—psoriasis	0.00411	0.0065	CbGbCtD
Regorafenib—CYP3A4—Cyclosporine—psoriasis	0.00389	0.00616	CbGbCtD
Regorafenib—FLT4—endothelium—psoriasis	0.00367	0.0715	CbGeAlD
Regorafenib—ABCB1—Methotrexate—psoriasis	0.00344	0.00544	CbGbCtD
Regorafenib—TEK—endothelium—psoriasis	0.00295	0.0575	CbGeAlD
Regorafenib—KIT—skin epidermis—psoriasis	0.00295	0.0574	CbGeAlD
Regorafenib—FLT1—endothelium—psoriasis	0.00286	0.0556	CbGeAlD
Regorafenib—DDR2—skin of body—psoriasis	0.00257	0.0501	CbGeAlD
Regorafenib—CYP3A4—Dexamethasone—psoriasis	0.00256	0.00405	CbGbCtD
Regorafenib—KDR—endothelium—psoriasis	0.00241	0.047	CbGeAlD
Regorafenib—KIT—endothelium—psoriasis	0.00214	0.0417	CbGeAlD
Regorafenib—DDR2—tendon—psoriasis	0.00196	0.0382	CbGeAlD
Regorafenib—BRAF—tendon—psoriasis	0.00139	0.027	CbGeAlD
Regorafenib—EPHX2—tendon—psoriasis	0.00132	0.0258	CbGeAlD
Regorafenib—FGFR2—skin of body—psoriasis	0.00132	0.0256	CbGeAlD
Regorafenib—RAF1—skin of body—psoriasis	0.00121	0.0236	CbGeAlD
Regorafenib—FGFR1—tendon—psoriasis	0.00118	0.0229	CbGeAlD
Regorafenib—RET—tendon—psoriasis	0.00105	0.0205	CbGeAlD
Regorafenib—EPHA2—tendon—psoriasis	0.000984	0.0192	CbGeAlD
Regorafenib—TEK—tendon—psoriasis	0.00096	0.0187	CbGeAlD
Regorafenib—FLT1—tendon—psoriasis	0.000928	0.0181	CbGeAlD
Regorafenib—RAF1—tendon—psoriasis	0.000923	0.018	CbGeAlD
Regorafenib—KIT—skin of body—psoriasis	0.000914	0.0178	CbGeAlD
Regorafenib—PDGFRB—skin of body—psoriasis	0.000892	0.0174	CbGeAlD
Regorafenib—PDGFRA—tendon—psoriasis	0.00087	0.0169	CbGeAlD
Regorafenib—ABL1—skin of body—psoriasis	0.000795	0.0155	CbGeAlD
Regorafenib—KDR—tendon—psoriasis	0.000785	0.0153	CbGeAlD
Regorafenib—PDGFRB—tendon—psoriasis	0.000679	0.0132	CbGeAlD
Regorafenib—ABL1—tendon—psoriasis	0.000605	0.0118	CbGeAlD
Regorafenib—CYP2B6—skin of body—psoriasis	0.000463	0.00901	CbGeAlD
Regorafenib—Haemorrhage—Hydrocortisone—psoriasis	0.000213	0.00136	CcSEcCtD
Regorafenib—Angiopathy—Mycophenolate mofetil—psoriasis	0.000212	0.00136	CcSEcCtD
Regorafenib—Alopecia—Cyclosporine—psoriasis	0.000211	0.00135	CcSEcCtD
Regorafenib—Mediastinal disorder—Mycophenolate mofetil—psoriasis	0.00021	0.00135	CcSEcCtD
Regorafenib—Dry skin—Prednisone—psoriasis	0.00021	0.00134	CcSEcCtD
Regorafenib—Connective tissue disorder—Hydrocortisone—psoriasis	0.000209	0.00134	CcSEcCtD
Regorafenib—Infection—Mycophenolic acid—psoriasis	0.000209	0.00134	CcSEcCtD
Regorafenib—Malnutrition—Cyclosporine—psoriasis	0.000208	0.00133	CcSEcCtD
Regorafenib—Hypokalaemia—Prednisone—psoriasis	0.000208	0.00133	CcSEcCtD
Regorafenib—Alopecia—Mycophenolate mofetil—psoriasis	0.000206	0.00132	CcSEcCtD
Regorafenib—Nervous system disorder—Mycophenolic acid—psoriasis	0.000206	0.00132	CcSEcCtD
Regorafenib—Thrombocytopenia—Mycophenolic acid—psoriasis	0.000206	0.00132	CcSEcCtD
Regorafenib—Weight decreased—Betamethasone—psoriasis	0.000205	0.00132	CcSEcCtD
Regorafenib—Weight decreased—Dexamethasone—psoriasis	0.000205	0.00132	CcSEcCtD
Regorafenib—Skin disorder—Mycophenolic acid—psoriasis	0.000204	0.00131	CcSEcCtD
Regorafenib—Malnutrition—Mycophenolate mofetil—psoriasis	0.000203	0.0013	CcSEcCtD
Regorafenib—Vomiting—Acitretin—psoriasis	0.000203	0.0013	CcSEcCtD
Regorafenib—Vomiting—Fluocinolone Acetonide—psoriasis	0.000203	0.0013	CcSEcCtD
Regorafenib—Alanine aminotransferase increased—Prednisone—psoriasis	0.000202	0.00129	CcSEcCtD
Regorafenib—Rash—Acitretin—psoriasis	0.000201	0.00129	CcSEcCtD
Regorafenib—Dermatitis—Acitretin—psoriasis	0.000201	0.00129	CcSEcCtD
Regorafenib—Haemoglobin—Triamcinolone—psoriasis	0.000201	0.00129	CcSEcCtD
Regorafenib—Rash—Fluocinolone Acetonide—psoriasis	0.000201	0.00129	CcSEcCtD
Regorafenib—Dermatitis—Fluocinolone Acetonide—psoriasis	0.000201	0.00129	CcSEcCtD
Regorafenib—Haemorrhage—Triamcinolone—psoriasis	0.0002	0.00128	CcSEcCtD
Regorafenib—Headache—Acitretin—psoriasis	0.0002	0.00128	CcSEcCtD
Regorafenib—Headache—Fluocinolone Acetonide—psoriasis	0.0002	0.00128	CcSEcCtD
Regorafenib—Acute coronary syndrome—Dexamethasone—psoriasis	0.000199	0.00128	CcSEcCtD
Regorafenib—Acute coronary syndrome—Betamethasone—psoriasis	0.000199	0.00128	CcSEcCtD
Regorafenib—Myocardial infarction—Dexamethasone—psoriasis	0.000198	0.00127	CcSEcCtD
Regorafenib—Myocardial infarction—Betamethasone—psoriasis	0.000198	0.00127	CcSEcCtD
Regorafenib—Body temperature increased—Hydroxyurea—psoriasis	0.000198	0.00127	CcSEcCtD
Regorafenib—Tremor—Cyclosporine—psoriasis	0.000195	0.00125	CcSEcCtD
Regorafenib—Anaemia—Cyclosporine—psoriasis	0.000192	0.00123	CcSEcCtD
Regorafenib—Tremor—Mycophenolate mofetil—psoriasis	0.00019	0.00122	CcSEcCtD
Regorafenib—Nausea—Acitretin—psoriasis	0.00019	0.00122	CcSEcCtD
Regorafenib—Nausea—Fluocinolone Acetonide—psoriasis	0.000189	0.00121	CcSEcCtD
Regorafenib—Anaemia—Mycophenolate mofetil—psoriasis	0.000188	0.0012	CcSEcCtD
Regorafenib—Leukopenia—Cyclosporine—psoriasis	0.000186	0.00119	CcSEcCtD
Regorafenib—Malnutrition—Hydrocortisone—psoriasis	0.000185	0.00119	CcSEcCtD
Regorafenib—Neutropenia—Prednisone—psoriasis	0.000185	0.00118	CcSEcCtD
Regorafenib—Decreased appetite—Mycophenolic acid—psoriasis	0.000183	0.00117	CcSEcCtD
Regorafenib—Haemoglobin—Dexamethasone—psoriasis	0.000183	0.00117	CcSEcCtD
Regorafenib—Haemoglobin—Betamethasone—psoriasis	0.000183	0.00117	CcSEcCtD
Regorafenib—Leukopenia—Mycophenolate mofetil—psoriasis	0.000182	0.00116	CcSEcCtD
Regorafenib—Haemorrhage—Betamethasone—psoriasis	0.000182	0.00116	CcSEcCtD
Regorafenib—Haemorrhage—Dexamethasone—psoriasis	0.000182	0.00116	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.000181	0.00116	CcSEcCtD
Regorafenib—Fatigue—Mycophenolic acid—psoriasis	0.000181	0.00116	CcSEcCtD
Regorafenib—Asthenia—Hydroxyurea—psoriasis	0.00018	0.00115	CcSEcCtD
Regorafenib—Hypertension—Cyclosporine—psoriasis	0.00018	0.00115	CcSEcCtD
Regorafenib—Pain—Mycophenolic acid—psoriasis	0.00018	0.00115	CcSEcCtD
Regorafenib—Weight decreased—Prednisone—psoriasis	0.000179	0.00115	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—psoriasis	0.000176	0.00113	CcSEcCtD
Regorafenib—Hypertension—Mycophenolate mofetil—psoriasis	0.000175	0.00112	CcSEcCtD
Regorafenib—Acute coronary syndrome—Prednisone—psoriasis	0.000174	0.00111	CcSEcCtD
Regorafenib—Dry mouth—Cyclosporine—psoriasis	0.000173	0.00111	CcSEcCtD
Regorafenib—Myocardial infarction—Prednisone—psoriasis	0.000173	0.00111	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Methotrexate—psoriasis	0.000172	0.0011	CcSEcCtD
Regorafenib—Gastrointestinal pain—Mycophenolic acid—psoriasis	0.000172	0.0011	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	0.000172	0.0011	CcSEcCtD
Regorafenib—Diarrhoea—Hydroxyurea—psoriasis	0.000172	0.0011	CcSEcCtD
Regorafenib—Dry mouth—Mycophenolate mofetil—psoriasis	0.000169	0.00108	CcSEcCtD
Regorafenib—Infection—Cyclosporine—psoriasis	0.000169	0.00108	CcSEcCtD
Regorafenib—Nervous system disorder—Cyclosporine—psoriasis	0.000167	0.00107	CcSEcCtD
Regorafenib—Thrombocytopenia—Cyclosporine—psoriasis	0.000166	0.00107	CcSEcCtD
Regorafenib—Body temperature increased—Mycophenolic acid—psoriasis	0.000166	0.00106	CcSEcCtD
Regorafenib—Abdominal pain—Mycophenolic acid—psoriasis	0.000166	0.00106	CcSEcCtD
Regorafenib—Skin disorder—Cyclosporine—psoriasis	0.000165	0.00106	CcSEcCtD
Regorafenib—Angiopathy—Dexamethasone—psoriasis	0.000165	0.00106	CcSEcCtD
Regorafenib—Angiopathy—Betamethasone—psoriasis	0.000165	0.00106	CcSEcCtD
Regorafenib—Infection—Mycophenolate mofetil—psoriasis	0.000165	0.00106	CcSEcCtD
Regorafenib—Hypertension—Prednisolone—psoriasis	0.000164	0.00105	CcSEcCtD
Regorafenib—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.000163	0.00104	CcSEcCtD
Regorafenib—Thrombocytopenia—Mycophenolate mofetil—psoriasis	0.000162	0.00104	CcSEcCtD
Regorafenib—Skin disorder—Mycophenolate mofetil—psoriasis	0.000161	0.00103	CcSEcCtD
Regorafenib—Alopecia—Dexamethasone—psoriasis	0.00016	0.00103	CcSEcCtD
Regorafenib—Alopecia—Betamethasone—psoriasis	0.00016	0.00103	CcSEcCtD
Regorafenib—Hypertension—Hydrocortisone—psoriasis	0.00016	0.00102	CcSEcCtD
Regorafenib—Vomiting—Hydroxyurea—psoriasis	0.000159	0.00102	CcSEcCtD
Regorafenib—Haemoglobin—Prednisone—psoriasis	0.000159	0.00102	CcSEcCtD
Regorafenib—Haemorrhage—Prednisone—psoriasis	0.000158	0.00101	CcSEcCtD
Regorafenib—Rash—Hydroxyurea—psoriasis	0.000158	0.00101	CcSEcCtD
Regorafenib—Dermatitis—Hydroxyurea—psoriasis	0.000158	0.00101	CcSEcCtD
Regorafenib—Headache—Hydroxyurea—psoriasis	0.000157	0.00101	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.000156	0.001	CcSEcCtD
Regorafenib—Connective tissue disorder—Prednisone—psoriasis	0.000155	0.000996	CcSEcCtD
Regorafenib—Neutropenia—Methotrexate—psoriasis	0.000154	0.000989	CcSEcCtD
Regorafenib—Asthenia—Mycophenolic acid—psoriasis	0.000151	0.000966	CcSEcCtD
Regorafenib—Hypertension—Triamcinolone—psoriasis	0.00015	0.000964	CcSEcCtD
Regorafenib—Infection—Hydrocortisone—psoriasis	0.00015	0.000961	CcSEcCtD
Regorafenib—Nausea—Hydroxyurea—psoriasis	0.000149	0.000955	CcSEcCtD
Regorafenib—Nervous system disorder—Hydrocortisone—psoriasis	0.000148	0.000949	CcSEcCtD
Regorafenib—Decreased appetite—Cyclosporine—psoriasis	0.000148	0.000947	CcSEcCtD
Regorafenib—Infestation NOS—Methotrexate—psoriasis	0.000147	0.000943	CcSEcCtD
Regorafenib—Infestation—Methotrexate—psoriasis	0.000147	0.000943	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000147	0.00094	CcSEcCtD
Regorafenib—Skin disorder—Hydrocortisone—psoriasis	0.000147	0.00094	CcSEcCtD
Regorafenib—Fatigue—Cyclosporine—psoriasis	0.000146	0.000939	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Methotrexate—psoriasis	0.000146	0.000935	CcSEcCtD
Regorafenib—Pain—Cyclosporine—psoriasis	0.000145	0.000931	CcSEcCtD
Regorafenib—Dry mouth—Triamcinolone—psoriasis	0.000145	0.00093	CcSEcCtD
Regorafenib—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000144	0.000923	CcSEcCtD
Regorafenib—Diarrhoea—Mycophenolic acid—psoriasis	0.000144	0.000921	CcSEcCtD
Regorafenib—Stomatitis—Methotrexate—psoriasis	0.000144	0.00092	CcSEcCtD
Regorafenib—Angiopathy—Prednisone—psoriasis	0.000143	0.000919	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000143	0.000917	CcSEcCtD
Regorafenib—Pain—Mycophenolate mofetil—psoriasis	0.000142	0.000908	CcSEcCtD
Regorafenib—Infection—Triamcinolone—psoriasis	0.000141	0.000905	CcSEcCtD
Regorafenib—Alopecia—Prednisone—psoriasis	0.00014	0.000896	CcSEcCtD
Regorafenib—Hepatobiliary disease—Methotrexate—psoriasis	0.000139	0.000892	CcSEcCtD
Regorafenib—Gastrointestinal pain—Cyclosporine—psoriasis	0.000139	0.00089	CcSEcCtD
Regorafenib—Malnutrition—Prednisone—psoriasis	0.000138	0.000882	CcSEcCtD
Regorafenib—Hypertension—Dexamethasone—psoriasis	0.000136	0.000875	CcSEcCtD
Regorafenib—Hypertension—Betamethasone—psoriasis	0.000136	0.000875	CcSEcCtD
Regorafenib—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000136	0.000869	CcSEcCtD
Regorafenib—Body temperature increased—Cyclosporine—psoriasis	0.000134	0.000861	CcSEcCtD
Regorafenib—Abdominal pain—Cyclosporine—psoriasis	0.000134	0.000861	CcSEcCtD
Regorafenib—Vomiting—Mycophenolic acid—psoriasis	0.000134	0.000856	CcSEcCtD
Regorafenib—Haemoglobin—Methotrexate—psoriasis	0.000133	0.000851	CcSEcCtD
Regorafenib—Rash—Mycophenolic acid—psoriasis	0.000132	0.000849	CcSEcCtD
Regorafenib—Dermatitis—Mycophenolic acid—psoriasis	0.000132	0.000848	CcSEcCtD
Regorafenib—Pain—Prednisolone—psoriasis	0.000132	0.000847	CcSEcCtD
Regorafenib—Haemorrhage—Methotrexate—psoriasis	0.000132	0.000847	CcSEcCtD
Regorafenib—Headache—Mycophenolic acid—psoriasis	0.000132	0.000843	CcSEcCtD
Regorafenib—Decreased appetite—Hydrocortisone—psoriasis	0.000131	0.000841	CcSEcCtD
Regorafenib—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000131	0.00084	CcSEcCtD
Regorafenib—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000131	0.00084	CcSEcCtD
Regorafenib—Urinary tract disorder—Methotrexate—psoriasis	0.000131	0.000836	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.00013	0.000835	CcSEcCtD
Regorafenib—Fatigue—Hydrocortisone—psoriasis	0.00013	0.000834	CcSEcCtD
Regorafenib—Urethral disorder—Methotrexate—psoriasis	0.00013	0.00083	CcSEcCtD
Regorafenib—Pain—Hydrocortisone—psoriasis	0.000129	0.000828	CcSEcCtD
Regorafenib—Infection—Dexamethasone—psoriasis	0.000128	0.000821	CcSEcCtD
Regorafenib—Infection—Betamethasone—psoriasis	0.000128	0.000821	CcSEcCtD
Regorafenib—Anaemia—Prednisone—psoriasis	0.000127	0.000815	CcSEcCtD
Regorafenib—Nervous system disorder—Betamethasone—psoriasis	0.000127	0.000811	CcSEcCtD
Regorafenib—Nervous system disorder—Dexamethasone—psoriasis	0.000127	0.000811	CcSEcCtD
Regorafenib—Thrombocytopenia—Betamethasone—psoriasis	0.000126	0.000809	CcSEcCtD
Regorafenib—Thrombocytopenia—Dexamethasone—psoriasis	0.000126	0.000809	CcSEcCtD
Regorafenib—Erythema multiforme—Methotrexate—psoriasis	0.000125	0.000801	CcSEcCtD
Regorafenib—Nausea—Mycophenolic acid—psoriasis	0.000125	0.000799	CcSEcCtD
Regorafenib—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000123	0.000791	CcSEcCtD
Regorafenib—Cardiac disorder—Methotrexate—psoriasis	0.000123	0.000786	CcSEcCtD
Regorafenib—Fatigue—Triamcinolone—psoriasis	0.000123	0.000786	CcSEcCtD
Regorafenib—Asthenia—Cyclosporine—psoriasis	0.000122	0.000781	CcSEcCtD
Regorafenib—Pain—Triamcinolone—psoriasis	0.000122	0.000779	CcSEcCtD
Regorafenib—Angiopathy—Methotrexate—psoriasis	0.00012	0.000768	CcSEcCtD
Regorafenib—Body temperature increased—Hydrocortisone—psoriasis	0.000119	0.000765	CcSEcCtD
Regorafenib—Abdominal pain—Hydrocortisone—psoriasis	0.000119	0.000765	CcSEcCtD
Regorafenib—Mediastinal disorder—Methotrexate—psoriasis	0.000119	0.000763	CcSEcCtD
Regorafenib—Asthenia—Mycophenolate mofetil—psoriasis	0.000119	0.000762	CcSEcCtD
Regorafenib—Hypertension—Prednisone—psoriasis	0.000119	0.000762	CcSEcCtD
Regorafenib—Alopecia—Methotrexate—psoriasis	0.000117	0.000748	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000116	0.000746	CcSEcCtD
Regorafenib—Diarrhoea—Cyclosporine—psoriasis	0.000116	0.000745	CcSEcCtD
Regorafenib—Malnutrition—Methotrexate—psoriasis	0.000115	0.000737	CcSEcCtD
Regorafenib—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000113	0.000727	CcSEcCtD
Regorafenib—Body temperature increased—Triamcinolone—psoriasis	0.000112	0.00072	CcSEcCtD
Regorafenib—Decreased appetite—Dexamethasone—psoriasis	0.000112	0.000719	CcSEcCtD
Regorafenib—Decreased appetite—Betamethasone—psoriasis	0.000112	0.000719	CcSEcCtD
Regorafenib—Infection—Prednisone—psoriasis	0.000112	0.000715	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Betamethasone—psoriasis	0.000111	0.000714	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000111	0.000714	CcSEcCtD
Regorafenib—Fatigue—Dexamethasone—psoriasis	0.000111	0.000713	CcSEcCtD
Regorafenib—Fatigue—Betamethasone—psoriasis	0.000111	0.000713	CcSEcCtD
Regorafenib—Pain—Betamethasone—psoriasis	0.00011	0.000707	CcSEcCtD
Regorafenib—Pain—Dexamethasone—psoriasis	0.00011	0.000707	CcSEcCtD
Regorafenib—Nervous system disorder—Prednisone—psoriasis	0.00011	0.000706	CcSEcCtD
Regorafenib—Skin disorder—Prednisone—psoriasis	0.000109	0.000699	CcSEcCtD
Regorafenib—Asthenia—Hydrocortisone—psoriasis	0.000108	0.000694	CcSEcCtD
Regorafenib—Vomiting—Cyclosporine—psoriasis	0.000108	0.000692	CcSEcCtD
Regorafenib—Rash—Cyclosporine—psoriasis	0.000107	0.000687	CcSEcCtD
Regorafenib—Dermatitis—Cyclosporine—psoriasis	0.000107	0.000686	CcSEcCtD
Regorafenib—Headache—Cyclosporine—psoriasis	0.000106	0.000682	CcSEcCtD
Regorafenib—Anaemia—Methotrexate—psoriasis	0.000106	0.000681	CcSEcCtD
Regorafenib—Gastrointestinal pain—Dexamethasone—psoriasis	0.000105	0.000676	CcSEcCtD
Regorafenib—Gastrointestinal pain—Betamethasone—psoriasis	0.000105	0.000676	CcSEcCtD
Regorafenib—Vomiting—Mycophenolate mofetil—psoriasis	0.000105	0.000675	CcSEcCtD
Regorafenib—Rash—Mycophenolate mofetil—psoriasis	0.000105	0.00067	CcSEcCtD
Regorafenib—Dermatitis—Mycophenolate mofetil—psoriasis	0.000104	0.000669	CcSEcCtD
Regorafenib—Headache—Mycophenolate mofetil—psoriasis	0.000104	0.000665	CcSEcCtD
Regorafenib—Diarrhoea—Hydrocortisone—psoriasis	0.000103	0.000662	CcSEcCtD
Regorafenib—Leukopenia—Methotrexate—psoriasis	0.000103	0.00066	CcSEcCtD
Regorafenib—Asthenia—Triamcinolone—psoriasis	0.000102	0.000654	CcSEcCtD
Regorafenib—Abdominal pain—Dexamethasone—psoriasis	0.000102	0.000654	CcSEcCtD
Regorafenib—Body temperature increased—Betamethasone—psoriasis	0.000102	0.000654	CcSEcCtD
Regorafenib—Body temperature increased—Dexamethasone—psoriasis	0.000102	0.000654	CcSEcCtD
Regorafenib—Abdominal pain—Betamethasone—psoriasis	0.000102	0.000654	CcSEcCtD
Regorafenib—Nausea—Cyclosporine—psoriasis	0.000101	0.000647	CcSEcCtD
Regorafenib—Nausea—Mycophenolate mofetil—psoriasis	9.85e-05	0.000631	CcSEcCtD
Regorafenib—Decreased appetite—Prednisone—psoriasis	9.77e-05	0.000626	CcSEcCtD
Regorafenib—Rash—Prednisolone—psoriasis	9.75e-05	0.000625	CcSEcCtD
Regorafenib—Dermatitis—Prednisolone—psoriasis	9.74e-05	0.000624	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	9.73e-05	0.000623	CcSEcCtD
Regorafenib—Fatigue—Prednisone—psoriasis	9.69e-05	0.000621	CcSEcCtD
Regorafenib—Headache—Prednisolone—psoriasis	9.69e-05	0.000621	CcSEcCtD
Regorafenib—Vomiting—Hydrocortisone—psoriasis	9.6e-05	0.000615	CcSEcCtD
Regorafenib—Rash—Hydrocortisone—psoriasis	9.52e-05	0.00061	CcSEcCtD
Regorafenib—Dermatitis—Hydrocortisone—psoriasis	9.51e-05	0.00061	CcSEcCtD
Regorafenib—Headache—Hydrocortisone—psoriasis	9.46e-05	0.000606	CcSEcCtD
Regorafenib—Infection—Methotrexate—psoriasis	9.33e-05	0.000598	CcSEcCtD
Regorafenib—Asthenia—Dexamethasone—psoriasis	9.26e-05	0.000593	CcSEcCtD
Regorafenib—Asthenia—Betamethasone—psoriasis	9.26e-05	0.000593	CcSEcCtD
Regorafenib—Nervous system disorder—Methotrexate—psoriasis	9.21e-05	0.00059	CcSEcCtD
Regorafenib—Thrombocytopenia—Methotrexate—psoriasis	9.19e-05	0.000589	CcSEcCtD
Regorafenib—Gastrointestinal pain—Prednisone—psoriasis	9.19e-05	0.000589	CcSEcCtD
Regorafenib—Nausea—Prednisolone—psoriasis	9.18e-05	0.000589	CcSEcCtD
Regorafenib—Skin disorder—Methotrexate—psoriasis	9.12e-05	0.000584	CcSEcCtD
Regorafenib—Vomiting—Triamcinolone—psoriasis	9.04e-05	0.000579	CcSEcCtD
Regorafenib—Nausea—Hydrocortisone—psoriasis	8.97e-05	0.000575	CcSEcCtD
Regorafenib—Rash—Triamcinolone—psoriasis	8.97e-05	0.000575	CcSEcCtD
Regorafenib—Dermatitis—Triamcinolone—psoriasis	8.96e-05	0.000574	CcSEcCtD
Regorafenib—Headache—Triamcinolone—psoriasis	8.91e-05	0.000571	CcSEcCtD
Regorafenib—Abdominal pain—Prednisone—psoriasis	8.88e-05	0.000569	CcSEcCtD
Regorafenib—Body temperature increased—Prednisone—psoriasis	8.88e-05	0.000569	CcSEcCtD
Regorafenib—Diarrhoea—Betamethasone—psoriasis	8.83e-05	0.000566	CcSEcCtD
Regorafenib—Diarrhoea—Dexamethasone—psoriasis	8.83e-05	0.000566	CcSEcCtD
Regorafenib—Nausea—Triamcinolone—psoriasis	8.45e-05	0.000541	CcSEcCtD
Regorafenib—Vomiting—Betamethasone—psoriasis	8.2e-05	0.000526	CcSEcCtD
Regorafenib—Vomiting—Dexamethasone—psoriasis	8.2e-05	0.000526	CcSEcCtD
Regorafenib—Decreased appetite—Methotrexate—psoriasis	8.16e-05	0.000523	CcSEcCtD
Regorafenib—Rash—Dexamethasone—psoriasis	8.13e-05	0.000521	CcSEcCtD
Regorafenib—Rash—Betamethasone—psoriasis	8.13e-05	0.000521	CcSEcCtD
Regorafenib—Dermatitis—Betamethasone—psoriasis	8.13e-05	0.000521	CcSEcCtD
Regorafenib—Dermatitis—Dexamethasone—psoriasis	8.13e-05	0.000521	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Methotrexate—psoriasis	8.11e-05	0.000519	CcSEcCtD
Regorafenib—Fatigue—Methotrexate—psoriasis	8.1e-05	0.000519	CcSEcCtD
Regorafenib—Headache—Dexamethasone—psoriasis	8.08e-05	0.000518	CcSEcCtD
Regorafenib—Headache—Betamethasone—psoriasis	8.08e-05	0.000518	CcSEcCtD
Regorafenib—Asthenia—Prednisone—psoriasis	8.06e-05	0.000517	CcSEcCtD
Regorafenib—Pain—Methotrexate—psoriasis	8.03e-05	0.000515	CcSEcCtD
Regorafenib—Diarrhoea—Prednisone—psoriasis	7.69e-05	0.000493	CcSEcCtD
Regorafenib—Gastrointestinal pain—Methotrexate—psoriasis	7.68e-05	0.000492	CcSEcCtD
Regorafenib—Nausea—Betamethasone—psoriasis	7.66e-05	0.000491	CcSEcCtD
Regorafenib—Nausea—Dexamethasone—psoriasis	7.66e-05	0.000491	CcSEcCtD
Regorafenib—Abdominal pain—Methotrexate—psoriasis	7.42e-05	0.000476	CcSEcCtD
Regorafenib—Body temperature increased—Methotrexate—psoriasis	7.42e-05	0.000476	CcSEcCtD
Regorafenib—Vomiting—Prednisone—psoriasis	7.14e-05	0.000458	CcSEcCtD
Regorafenib—Rash—Prednisone—psoriasis	7.08e-05	0.000454	CcSEcCtD
Regorafenib—Dermatitis—Prednisone—psoriasis	7.08e-05	0.000454	CcSEcCtD
Regorafenib—Headache—Prednisone—psoriasis	7.04e-05	0.000451	CcSEcCtD
Regorafenib—Asthenia—Methotrexate—psoriasis	6.74e-05	0.000432	CcSEcCtD
Regorafenib—Nausea—Prednisone—psoriasis	6.67e-05	0.000428	CcSEcCtD
Regorafenib—Diarrhoea—Methotrexate—psoriasis	6.42e-05	0.000412	CcSEcCtD
Regorafenib—Vomiting—Methotrexate—psoriasis	5.97e-05	0.000383	CcSEcCtD
Regorafenib—Rash—Methotrexate—psoriasis	5.92e-05	0.000379	CcSEcCtD
Regorafenib—Dermatitis—Methotrexate—psoriasis	5.92e-05	0.000379	CcSEcCtD
Regorafenib—Headache—Methotrexate—psoriasis	5.88e-05	0.000377	CcSEcCtD
Regorafenib—Nausea—Methotrexate—psoriasis	5.58e-05	0.000357	CcSEcCtD
Regorafenib—PDGFRB—Disease—NOS2—psoriasis	1.11e-05	6.94e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP2S1—psoriasis	1.11e-05	6.92e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—IFNG—psoriasis	1.1e-05	6.89e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—TYK2—psoriasis	1.1e-05	6.86e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—TYK2—psoriasis	1.1e-05	6.84e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—TYK2—psoriasis	1.09e-05	6.79e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—LEP—psoriasis	1.09e-05	6.79e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—APOE—psoriasis	1.09e-05	6.79e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—IFNG—psoriasis	1.08e-05	6.76e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.08e-05	6.76e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—ICAM1—psoriasis	1.08e-05	6.76e-05	CbGpPWpGaD
Regorafenib—MAPK11—Innate Immune System—IL6—psoriasis	1.08e-05	6.73e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—LEP—psoriasis	1.08e-05	6.72e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—APOE—psoriasis	1.08e-05	6.72e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—NFKBIA—psoriasis	1.07e-05	6.7e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—TYK2—psoriasis	1.07e-05	6.67e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—CD4—psoriasis	1.07e-05	6.65e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—APOE—psoriasis	1.06e-05	6.64e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—CD4—psoriasis	1.06e-05	6.63e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—CD4—psoriasis	1.05e-05	6.53e-05	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.05e-05	6.52e-05	CbGpPWpGaD
Regorafenib—FGFR1—Developmental Biology—IL6—psoriasis	1.04e-05	6.52e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—JUN—psoriasis	1.04e-05	6.48e-05	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—TP53—psoriasis	1.04e-05	6.48e-05	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—TNF—psoriasis	1.04e-05	6.47e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—IFNG—psoriasis	1.03e-05	6.42e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—IFNG—psoriasis	1.03e-05	6.4e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—VEGFA—psoriasis	1.03e-05	6.4e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—TYK2—psoriasis	1.02e-05	6.37e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—STAT3—psoriasis	1.02e-05	6.34e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—TYK2—psoriasis	1.01e-05	6.33e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—NFKBIA—psoriasis	1.01e-05	6.32e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—TYK2—psoriasis	1.01e-05	6.31e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—SOCS1—psoriasis	1.01e-05	6.3e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—CARM1—psoriasis	1.01e-05	6.3e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—NFKBIA—psoriasis	1e-05	6.26e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—CAT—psoriasis	1e-05	6.24e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—NFKB1—psoriasis	1e-05	6.24e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—APOE—psoriasis	9.98e-06	6.23e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—LEP—psoriasis	9.98e-06	6.23e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—CD4—psoriasis	9.93e-06	6.2e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—NOS2—psoriasis	9.92e-06	6.19e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—CD4—psoriasis	9.91e-06	6.18e-05	CbGpPWpGaD
Regorafenib—FGFR2—Innate Immune System—IL6—psoriasis	9.9e-06	6.18e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—TYK2—psoriasis	9.87e-06	6.16e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—CD4—psoriasis	9.84e-06	6.14e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—APOE—psoriasis	9.8e-06	6.12e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—LEP—psoriasis	9.8e-06	6.12e-05	CbGpPWpGaD
Regorafenib—ABL1—Hemostasis—TP53—psoriasis	9.8e-06	6.12e-05	CbGpPWpGaD
Regorafenib—KIT—Innate Immune System—IL6—psoriasis	9.72e-06	6.07e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.67e-06	6.03e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—CD4—psoriasis	9.66e-06	6.03e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—TYK2—psoriasis	9.65e-06	6.02e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—TYK2—psoriasis	9.63e-06	6.01e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—TYK2—psoriasis	9.62e-06	6e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—JUN—psoriasis	9.54e-06	5.95e-05	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—IL6—psoriasis	9.51e-06	5.93e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.44e-06	5.89e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—JUN—psoriasis	9.37e-06	5.85e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—LEP—psoriasis	9.3e-06	5.81e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—APOE—psoriasis	9.3e-06	5.81e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—NFKBIA—psoriasis	9.3e-06	5.81e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—LEP—psoriasis	9.28e-06	5.79e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—APOE—psoriasis	9.28e-06	5.79e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IFNG—psoriasis	9.24e-06	5.77e-05	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—IL6—psoriasis	9.22e-06	5.76e-05	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	9.22e-06	5.75e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—IL6—psoriasis	9.2e-06	5.74e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—NFKB1—psoriasis	9.18e-06	5.73e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—CD4—psoriasis	9.17e-06	5.72e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—APOE—psoriasis	9.16e-06	5.72e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—APOE—psoriasis	9.16e-06	5.72e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—CD4—psoriasis	9.15e-06	5.71e-05	CbGpPWpGaD
Regorafenib—ABL1—Developmental Biology—IL6—psoriasis	9.15e-06	5.71e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—NFKBIA—psoriasis	9.14e-06	5.7e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—TYK2—psoriasis	9.11e-06	5.69e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—NFKB1—psoriasis	9.02e-06	5.63e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—CARM1—psoriasis	9.01e-06	5.62e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IFNG—psoriasis	9.01e-06	5.62e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—STAT3—psoriasis	8.99e-06	5.61e-05	CbGpPWpGaD
Regorafenib—RAF1—Hemostasis—TP53—psoriasis	8.96e-06	5.6e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—CD4—psoriasis	8.93e-06	5.57e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—CXCL8—psoriasis	8.89e-06	5.55e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—JUN—psoriasis	8.89e-06	5.55e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—JUN—psoriasis	8.87e-06	5.53e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.82e-06	5.5e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—TYK2—psoriasis	8.8e-06	5.49e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—CARM1—psoriasis	8.79e-06	5.49e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—CD4—psoriasis	8.7e-06	5.43e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—NFKBIA—psoriasis	8.67e-06	5.41e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—NFKBIA—psoriasis	8.65e-06	5.4e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—NFKB1—psoriasis	8.56e-06	5.34e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—NFKB1—psoriasis	8.54e-06	5.33e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.42e-06	5.26e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—CXCL8—psoriasis	8.4e-06	5.24e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—CXCL8—psoriasis	8.38e-06	5.23e-05	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—IL6—psoriasis	8.36e-06	5.22e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—APOE—psoriasis	8.36e-06	5.22e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—LEP—psoriasis	8.36e-06	5.22e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—TYK2—psoriasis	8.3e-06	5.18e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—IL6—psoriasis	8.29e-06	5.17e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—JUN—psoriasis	8.27e-06	5.16e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—STAT3—psoriasis	8.25e-06	5.15e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—CD4—psoriasis	8.24e-06	5.14e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IFNG—psoriasis	8.24e-06	5.14e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—TYK2—psoriasis	8.22e-06	5.13e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—STAT3—psoriasis	8.22e-06	5.13e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CARM1—psoriasis	8.22e-06	5.13e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—TYK2—psoriasis	8.12e-06	5.07e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—STAT3—psoriasis	8.1e-06	5.06e-05	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—IL6—psoriasis	8.08e-06	5.04e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—JUN—psoriasis	7.99e-06	4.99e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—PPARG—psoriasis	7.98e-06	4.98e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—PPARG—psoriasis	7.98e-06	4.98e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—NFKB1—psoriasis	7.96e-06	4.97e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—CD4—psoriasis	7.96e-06	4.97e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—JUN—psoriasis	7.81e-06	4.88e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—NFKBIA—psoriasis	7.79e-06	4.86e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—JUN—psoriasis	7.79e-06	4.86e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—APOE—psoriasis	7.77e-06	4.85e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—TP53—psoriasis	7.75e-06	4.84e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—STAT3—psoriasis	7.69e-06	4.8e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—NFKB1—psoriasis	7.69e-06	4.8e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.68e-06	4.79e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—STAT3—psoriasis	7.67e-06	4.79e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TYK2—psoriasis	7.62e-06	4.76e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—STAT3—psoriasis	7.62e-06	4.75e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—NFKB1—psoriasis	7.52e-06	4.69e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—NFKB1—psoriasis	7.49e-06	4.68e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TYK2—psoriasis	7.48e-06	4.67e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—STAT3—psoriasis	7.48e-06	4.67e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—LEP—psoriasis	7.45e-06	4.65e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—APOE—psoriasis	7.45e-06	4.65e-05	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—IL6—psoriasis	7.39e-06	4.61e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—CD4—psoriasis	7.35e-06	4.58e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—CAT—psoriasis	7.33e-06	4.58e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—CXCL8—psoriasis	7.23e-06	4.51e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—VEGFA—psoriasis	7.22e-06	4.51e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—CXCL8—psoriasis	7.16e-06	4.47e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—STAT3—psoriasis	7.15e-06	4.46e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—JUN—psoriasis	7.12e-06	4.44e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TYK2—psoriasis	7.1e-06	4.43e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—STAT3—psoriasis	7.1e-06	4.43e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—IL6—psoriasis	7.09e-06	4.43e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TYK2—psoriasis	7.08e-06	4.42e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—STAT3—psoriasis	7.08e-06	4.42e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—NFKBIA—psoriasis	6.94e-06	4.33e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—STAT3—psoriasis	6.91e-06	4.31e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—NFKB1—psoriasis	6.85e-06	4.28e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—VEGFA—psoriasis	6.82e-06	4.26e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PPARG—psoriasis	6.77e-06	4.23e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—STAT3—psoriasis	6.76e-06	4.22e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—STAT3—psoriasis	6.74e-06	4.2e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—JUN—psoriasis	6.72e-06	4.19e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—JUN—psoriasis	6.65e-06	4.15e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CXCL8—psoriasis	6.63e-06	4.14e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CXCL8—psoriasis	6.52e-06	4.07e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—NFKB1—psoriasis	6.47e-06	4.04e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—NFKB1—psoriasis	6.41e-06	4e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TYK2—psoriasis	6.38e-06	3.98e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—STAT3—psoriasis	6.38e-06	3.98e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—IL6—psoriasis	6.28e-06	3.92e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—CAT—psoriasis	6.21e-06	3.88e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CXCL8—psoriasis	6.18e-06	3.86e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CXCL8—psoriasis	6.17e-06	3.85e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—JUN—psoriasis	6.17e-06	3.85e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—STAT3—psoriasis	6.16e-06	3.84e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—JUN—psoriasis	6.06e-06	3.78e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—NFKB1—psoriasis	5.94e-06	3.71e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—VEGFA—psoriasis	5.87e-06	3.66e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—NFKB1—psoriasis	5.83e-06	3.64e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—VEGFA—psoriasis	5.81e-06	3.63e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—STAT3—psoriasis	5.81e-06	3.63e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—IL6—psoriasis	5.76e-06	3.6e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—STAT3—psoriasis	5.76e-06	3.59e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—JUN—psoriasis	5.75e-06	3.59e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—IL6—psoriasis	5.74e-06	3.58e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—JUN—psoriasis	5.73e-06	3.58e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—APOE—psoriasis	5.7e-06	3.56e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TYK2—psoriasis	5.69e-06	3.55e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—STAT3—psoriasis	5.69e-06	3.55e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—IL6—psoriasis	5.66e-06	3.53e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CXCL8—psoriasis	5.56e-06	3.47e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—CAT—psoriasis	5.54e-06	3.46e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—NFKB1—psoriasis	5.53e-06	3.45e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—NFKB1—psoriasis	5.52e-06	3.44e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—TP53—psoriasis	5.46e-06	3.41e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CARM1—psoriasis	5.42e-06	3.38e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—CAT—psoriasis	5.41e-06	3.38e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—VEGFA—psoriasis	5.39e-06	3.36e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—IL6—psoriasis	5.37e-06	3.35e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—IL6—psoriasis	5.36e-06	3.34e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—STAT3—psoriasis	5.34e-06	3.33e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—IL6—psoriasis	5.32e-06	3.32e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—VEGFA—psoriasis	5.29e-06	3.3e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—STAT3—psoriasis	5.24e-06	3.27e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—IL6—psoriasis	5.23e-06	3.26e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—JUN—psoriasis	5.17e-06	3.22e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—TP53—psoriasis	5.16e-06	3.22e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CAT—psoriasis	5.05e-06	3.15e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—VEGFA—psoriasis	5.02e-06	3.13e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—VEGFA—psoriasis	5.01e-06	3.13e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—IL6—psoriasis	4.99e-06	3.12e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—STAT3—psoriasis	4.97e-06	3.1e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—NFKB1—psoriasis	4.97e-06	3.1e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PPARG—psoriasis	4.96e-06	3.1e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—IL6—psoriasis	4.96e-06	3.1e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—STAT3—psoriasis	4.96e-06	3.1e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CXCL8—psoriasis	4.95e-06	3.09e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—IL6—psoriasis	4.95e-06	3.09e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IL6—psoriasis	4.83e-06	3.01e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—APOE—psoriasis	4.82e-06	3.01e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—IL6—psoriasis	4.72e-06	2.95e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—IL6—psoriasis	4.71e-06	2.94e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IL6—psoriasis	4.7e-06	2.94e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—JUN—psoriasis	4.6e-06	2.87e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—VEGFA—psoriasis	4.51e-06	2.82e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—STAT3—psoriasis	4.47e-06	2.79e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—IL6—psoriasis	4.46e-06	2.78e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—TP53—psoriasis	4.43e-06	2.77e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—NFKB1—psoriasis	4.43e-06	2.77e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—TP53—psoriasis	4.39e-06	2.74e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—APOE—psoriasis	4.31e-06	2.69e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IL6—psoriasis	4.3e-06	2.69e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—APOE—psoriasis	4.2e-06	2.62e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PPARG—psoriasis	4.2e-06	2.62e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TP53—psoriasis	4.07e-06	2.54e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—IL6—psoriasis	4.06e-06	2.53e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—VEGFA—psoriasis	4.02e-06	2.51e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—IL6—psoriasis	4.02e-06	2.51e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TP53—psoriasis	4e-06	2.5e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—STAT3—psoriasis	3.98e-06	2.49e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—IL6—psoriasis	3.97e-06	2.48e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—APOE—psoriasis	3.93e-06	2.45e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TP53—psoriasis	3.79e-06	2.37e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TP53—psoriasis	3.78e-06	2.36e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PPARG—psoriasis	3.75e-06	2.34e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—IL6—psoriasis	3.73e-06	2.33e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PPARG—psoriasis	3.66e-06	2.28e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IL6—psoriasis	3.66e-06	2.28e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IL6—psoriasis	3.47e-06	2.17e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IL6—psoriasis	3.46e-06	2.16e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PPARG—psoriasis	3.42e-06	2.13e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TP53—psoriasis	3.41e-06	2.13e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CAT—psoriasis	3.33e-06	2.08e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IL6—psoriasis	3.12e-06	1.95e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TP53—psoriasis	3.04e-06	1.9e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL6—psoriasis	2.78e-06	1.74e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—APOE—psoriasis	2.59e-06	1.62e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PPARG—psoriasis	2.26e-06	1.41e-05	CbGpPWpGaD
